<?xml version="1.0" encoding="UTF-8"?>
<ref id="B32-biomolecules-11-00272">
 <label>32.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rosenthal</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Delaunay</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Jeandel</surname>
    <given-names>P.Y.</given-names>
   </name>
   <name>
    <surname>Haas</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Pomares-Estran</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Marty</surname>
    <given-names>P.</given-names>
   </name>
  </person-group>
  <article-title>Le traitement de la leishmaniose viscérale en Europe en 2009. Place de l’amphotéricine B liposomale</article-title>
  <source>Med. Mal. Infect.</source>
  <year>2009</year>
  <volume>39</volume>
  <fpage>741</fpage>
  <lpage>744</lpage>
  <comment>(In French)</comment>
  <pub-id pub-id-type="doi">10.1016/j.medmal.2009.05.001</pub-id>
  <pub-id pub-id-type="pmid">19783391</pub-id>
 </element-citation>
</ref>
